No Data
Express News | Shares of Vaccine and Gene Therapy Stocks Are Trading Lower After FDA Commissioner Marty Makary Reportedly Named Vinay Prasad as Director of the Center for Biologics and Research
Express News | 'FDA Names Vinay Prasad as New Head of Vaccines, Biologics'- Bloomberg Law
UBS Adjusts Biohaven Price Target to $40 From $65, Maintains Buy Rating
Biohaven Secures $600m Financing as It Awaits FDA Prodrug Decision
Baird Maintains Biohaven(BHVN.US) With Buy Rating, Cuts Target Price to $57
Why BioHaven Stock Is Soaring Today